Left ventricular thrombus following axitinib plus toripalimab therapy in metastatic clear cell renal cell carcinoma: a case report

Background The combination of vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs) and programmed cell death protein 1 (PD-1) inhibitors has become a standard first-line treatment for advanced clear cell renal cell carcinoma (ccRCC). However, cardiovascular toxicities associated with this combination require further clinical attention. Here, we report a rare case of left ventricular (LV) thrombus occurring following axitinib plus toripalimab therapy in metastatic ccRCC and discuss its clinical management strategy. Case presentation A 60-year-old woman with stage IV ccRCC (cT2aN1M1) and bilateral pulmonary metastases achieved a partial response after two cycles of axitinib (5 mg twice daily) combined with toripalimab (240 mg every 21 days). After two cycles at month 1.5, Grade 3 immune-related hepatitis developed, requiring discontinuation of both toripalimab and axitinib, followed by prolonged corticosteroid therapy. After four weeks of corticosteroid treatment, liver transaminases improved, prompting the resumption of axitinib monotherapy while corticosteroids were completely tapered off over a total course of five weeks. Three months after starting initial combination therapy, corresponding to approximately two weeks after axitinib resumption, the patient presented with exertional fatigue. Echocardiography revealed a heterogeneous hyperechoic mass in the mid-anterior wall of the left ventricle with reduced left ventricular ejection fraction (46%). Contrast-enhanced computed tomography (CT) further confirmed the presence of an LV thrombus. Axitinib was discontinued, and anticoagulation therapy with nadroparin calcium followed by warfarin was initiated. Complete thrombus resolution was achieved after three months; however, prolonged interruption of antineoplastic therapy was followed by disease progression. Conclusion This case highlights LV thrombus as a complex, multifactorial cardiovascular event occurring during the course of VEGFR-TKI and ICI therapy in advanced ccRCC. Careful cardiovascular monitoring and multidisciplinary management are essential for early recognition and individualized treatment of this potentially serious complication.

Authors

Publication Details

Journal
Frontiers in Immunology
Published
2026-11-12
DOI
https://doi.org/10.3389/fimmu.2026.1992399
Primary Topic
Cardiac tumors and thrombi
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Left ventricular thrombus following axitinib plus toripalimab therapy in metastatic clear cell renal cell carcinoma: a case report

Ting Zhong, Jiani Mo, Juan Liang, Lianxi Song et al.
Frontiers in Immunology
Cardiac tumors and thrombi
article

Left ventricular thrombus following axitinib plus toripalimab therapy in metastatic clear cell renal cell carcinoma: a case report

Ting Zhong, Jiani Mo, Juan Liang, Lianxi Song, Xiaolong Zhou, Feng Chen
article en

Abstract

Background The combination of vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs) and programmed cell death protein 1 (PD-1) inhibitors has become a standard first-line treatment for advanced clear cell renal cell carcinoma (ccRCC). However, cardiovascular toxicities associated with this combination require further clinical attention. Here, we report a rare case of left ventricular (LV) thrombus occurring following axitinib plus toripalimab therapy in metastatic ccRCC and discuss its clinical management strategy. Case presentation A 60-year-old woman with stage IV ccRCC (cT2aN1M1) and bilateral pulmonary metastases achieved a partial response after two cycles of axitinib (5 mg twice daily) combined with toripalimab (240 mg every 21 days). After two cycles at month 1.5, Grade 3 immune-related hepatitis developed, requiring discontinuation of both toripalimab and axitinib, followed by prolonged corticosteroid therapy. After four weeks of corticosteroid treatment, liver transaminases improved, prompting the resumption of axitinib monotherapy while corticosteroids were completely tapered off over a total course of five weeks. Three months after starting initial combination therapy, corresponding to approximately two weeks after axitinib resumption, the patient presented with exertional fatigue. Echocardiography revealed a heterogeneous hyperechoic mass in the mid-anterior wall of the left ventricle with reduced left ventricular ejection fraction (46%). Contrast-enhanced computed tomography (CT) further confirmed the presence of an LV thrombus. Axitinib was discontinued, and anticoagulation therapy with nadroparin calcium followed by warfarin was initiated. Complete thrombus resolution was achieved after three months; however, prolonged interruption of antineoplastic therapy was followed by disease progression. Conclusion This case highlights LV thrombus as a complex, multifactorial cardiovascular event occurring during the course of VEGFR-TKI and ICI therapy in advanced ccRCC. Careful cardiovascular monitoring and multidisciplinary management are essential for early recognition and individualized treatment of this potentially serious complication.

Frontiers in ImmunologyVol. 17
Good health and well-being
Cardiac tumors and thrombi
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon